RNS Number : 6317P
ValiRx PLC
18 February 2021

("ValiRx", the "Company" or the "Group")

Director/PDMR Shareholdings

London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces that it has received notifications on 18 February 2021 of the following share purchases by certain Directors and PDMRs of the Company.

Name	Number of shares purchased	Purchase price	Date of purchase	Number of shares held prior to purchase	Number of shares held following purchase	Percentage shareholding of issued share capital following purchase
Kevin Cox (Director)	22,000	22.25p	17/02/2021	250,333	272,333	0.42%
Gerry Desler (Director)	22,000	22.75p	18/02/2021	81,668	103,668	0.16%
Martin Lampshire (Director)	44,000	22.70p	18/02/2021	-	44,000	0.07%
Mark Treharne (PDMR)	6,095	22.78p	17/02/2021	-	6,095	0.01%

Exercise of Warrants

Furthermore, the Company received notifications on 18 February 2021 for the exercise of warrants over 166,666 new ordinary shares in the Company at an exercise price of 13p each ("New Ordinary Shares") by Suzanne Dilly and Kevin Alexander, both Directors of the Company. Details of the exercise are set out in the table below.

Name	Number of	Purchase	Number of	Number	Percentage

	warrants exercised	price	shares held prior to purchase	of shares held following exercise	shareholding of issued share capital following exercise
Suzanne Dilly	83,333	13.00p	233,335	316,668	0.49%
Kevin Alexander	83,333	13.00p	167,500	250,833	0.39%

Total Voting Rights

The Company had previously applied to list these 166,666 ordinary shares as part of the block listing of 9,034,732 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") which was announced on 19 August 2020. They were admitted to trading on AIM on 24 August 2020.

The total voting rights of the Company comprise 65,049,156 Ordinary Shares which may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Ends

For further information please contact:

ValiRx plc **Tel: +44 (0) 2476 796496**
www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser) **Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Sole Broker) **Tel: +44 (0) 20 7469 0930**
Duncan Vasey / Lucy Williams / Eran Zucker

Optimum Strategic Communications **Tel: +44 (0) 20 8148 3040**
Supriya Mathur/ Shabnam Bashir valirx@optimumcomms.com

About ValiRx plc
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	**Details of the person discharging managerial responsibilities/person closely associated**	
a.	Name	a) Kevin Cox b) Gerry Desler c) Martin Lampshire d) Mark Treharne
2	**Reason for notification**	
a.	Position/Status	a) Director b) Director c) Director d) PDMR

b.	Initial notification/ Amendment	Initial notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a.	Name	ValiRx PLC
b.	LEI	213800VQKB9SJCQDET40
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BLH13C52
b.	Nature of the transaction	On market Purchase
c.	Price(s) and volume(s)	

Price(s)	Volume(s)
a) £ 0.22250 b) £ 0.22745 c) £ 0.22700 d) £ 0.22780	a) 22,000 b) 22,000 c) 44,000 d) 6,095

d.	Aggregated information	

	- Aggregated Volume - Price	94,095 £0.22610 (weighted average price)
e.	Date of the transaction	a) 17/02/2021 b) 18/02/2021 c) 18/02/2021 d) 17/02/2021
f.	Place of the transaction	London, UK

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	**Details of the person discharging managerial responsibilities/person closely associated**	
a.	Name	a) Suzanne Dilly b) Kevin Alexander
2	**Reason for notification**	
a.	Position/Status	a) Director b) Director
b.	Initial notification/ Amendment	Initial notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a.	Name	ValiRx PLC
b.	LEI	213800VQKB9SJCQDET40

4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a.	Description of the financial instrument, type of instrument Identification Code	Warrants over new ordinary shares ISIN: GB00BLH13C52
b.	Nature of the transaction	Exercise of warrants over new ordinary shares at an exercise price of 13p per share
c.	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>a) £0.13 b) £0.13</td><td>83,333 83,333</td></tr></table>
d.	Aggregated information - Aggregated Volume - Price	166,666 £0.13
e.	Date of the transaction	18/02/2021
f.	Place of the transaction	London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to

the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUGDDLXBDGBI